E!5995, NIAC, IVRS AB

Purpose and goal

** Denna text är maskinöversatt ** The project aims to accelerate the development of an Thymidine Phosphorylase (TP) inhibitor for the treatment of drug-resistant advanced kidney cancer. TP is an enzyme that plays a critical role in tumor growth and resistance to treatments that inhibit blood vessel formation. By combining a TP inhibitor with these treatments, the antitumor effect is enhanced. Preclinical data have shown that TP expression in cancer cells affects the tumor becoming resistant to anti-vascular treatment.

Expected effects and result

** Denna text är maskinöversatt ** The consortium will present preclinical data for an inhibitor that targets resistant tumor cells in treating kidney cancer. This aims to prolong the survival of patients who no longer respond to standard treatments. Proof-of-concept studies will be performed in innovative 3D models of human kidney cancer in vitro and in animal models in vivo. The goal is to collect sufficient data to start clinical trials when the project is finalized.

Planned approach and implementation

** Denna text är maskinöversatt ** The study identifies promising candidates that both effectively inhibit TP and have favorable ADME properties. These lead candidates are being optimized and tested preclinically. In vitro tests take place in 3D models based on samples from kidney cancer patients. IVRS will conduct safety studies in mouse models, combined with advanced imaging techniques. These models together are important to ensure preclinical validation for future drug development.